Alnylam Pharmaceuticals announced the appointment of Carolyn Bertozzi, Ph.D. a Nobel Laureate to the Board. Dr. Bertozzi is known is known for her work in chemical biology. She is a pioneer for emerging technology and has founded ten biopharmaceutical companies and guided more than a dozen academic and professional organizations and life sciences companies in leadership and board positions. Alnylam also announced that Board member and Lead Independent Director Amy W. Schulman, will assume the role of Chair of the Board from Michael W. Bonney, who will continue on the Board as a non-independent director. Mr. Bonney will be stepping down from his interim role as Executive Chair where he was focused on integrating the ethics and compliance function at Alnylam, a role he assumed for just over a year during which the company appointed a new Chief Ethics and Compliance Officer.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ALNY:
- Alnylam submits CTA application for type 2 diabetes treatment ALN-KHK
- Ionis assumed with Equal Weight from Overweight at Morgan Stanley
- Alnylam price target raised to $253 from $226 at Piper Sandler
- Alnylam to host virtual research and development day
- Biotech Alert: Searches spiking for these stocks today